Stryker (NYSE:SYK) Shares Unloaded Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on November 20th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.
• Sold $15,001 – $50,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/20/2025.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 9/25/2025.

Stryker Stock Performance

NYSE:SYK opened at $355.21 on Monday. The firm’s 50-day moving average is $365.26 and its 200-day moving average is $377.45. The company has a market cap of $135.84 billion, a price-to-earnings ratio of 46.68, a PEG ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the firm posted $2.87 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio is presently 44.15%.

Insider Activity

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 522,118 shares of company stock valued at $185,381,932 in the last 90 days. 5.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on SYK. Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a research report on Friday. Barclays raised their price target on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Wells Fargo & Company increased their target price on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Truist Financial cut their target price on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research report on Thursday. Finally, Evercore ISI lowered their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $431.84.

Institutional Trading of Stryker

Several large investors have recently made changes to their positions in SYK. Mirabella Financial Services LLP increased its position in Stryker by 124.4% in the third quarter. Mirabella Financial Services LLP now owns 10,248 shares of the medical technology company’s stock worth $3,781,000 after purchasing an additional 5,681 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Stryker during the third quarter worth approximately $55,000. Hudson Bay Capital Management LP lifted its holdings in Stryker by 130.5% in the third quarter. Hudson Bay Capital Management LP now owns 568 shares of the medical technology company’s stock valued at $210,000 after buying an additional 2,430 shares during the period. Severin Investments LLC boosted its stake in Stryker by 24.1% in the third quarter. Severin Investments LLC now owns 1,499 shares of the medical technology company’s stock valued at $554,000 after acquiring an additional 291 shares during the last quarter. Finally, Swiss Life Asset Management Ltd grew its holdings in Stryker by 7.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 37,984 shares of the medical technology company’s stock worth $14,042,000 after acquiring an additional 2,486 shares during the period. Institutional investors own 77.09% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.